News

Here are Cathie Wood’s latest moves.

Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu

On September 17, Ferrari N.V. (NYSE:RACE) announced a partnership with the technology company Rakuten Group, Inc., effective January 1, 2027. The announcement gives no scope and no price tag, so it works better as a signal than as a number. The real substance sits in the results Ferrari posted on July 30, when it raised […]

A volatile week saw AI regulation fears hit chip stocks before a recovery, with MarketBeat writers covering Micron, Nike, Tesla, Rocket Lab, Adobe, SpaceX and other stocks ahead of key inflation and jobs data.

Squatters took over several abandoned Brewdog pubs after the company collapsed, administrators said.

Outsize Social Security raises come with a silver lining for tens of millions of retirees, but also the potential for serious consequences.

When the Nasdaq craters, the gap between 2x and 3x leverage stops being an academic footnote and starts costing real money. What investors in TQQQ discover the hard way, QLD holders already knew.

On August 20, Royal Caribbean Group (NYSE:RCL) said it had completed a sale of $1.25 billion of notes that carry a 5.55% coupon and come due on January 20, 2034. The money is earmarked first for floating-rate term loans, with anything left over used to repay or refinance other debt, and the offering rode on […]

How does $20,000-plus in annual dividend income sound?

Warren Buffett became the world’s most famous investor by betting on the boring stuff.

On August 6, Wheaton Precious Metals (NYSE:WPM) reported second-quarter net earnings of $543 million on $929 million of revenue, both records. Through the first half, net earnings rose 106% to $1.1 billion. During the quarter, the company also made net upfront cash payments of $4.5 billion relative to mineral stream interests, and it now carries […]

L3Harris's VAMPIRE rockets were already popular. And now they've got AI.

Will one great product make AeroVironment stock a great investment?

Given the number of American seniors who live on Social Security alone, it's important to know where to turn for help.

The agent economy is not being enabled by software; it is being bottlenecked by hardware. While the popular imagination fixates on autonomous code orchestrating value, the actual mechanism of the current market is far more terrestrial. If you cannot power it, you cannot run it. This is the governing rule of the AI era, and […]

Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...

Key TakeawaysCloudflare’s Q2 beat and reaccelerating growth (36% revenue growth, 120% net dollar retention, record large customer adds) pushed NET stock to new highs, but the market has already paid up: NTM EV/Revenue sits at 35. 17x, just below its all-time high of 36.

In recent days, AngloGold Ashanti has attracted attention as analysts projected a very large year-over-year increase in quarterly earnings per share alongside solid revenue growth, supported by updated consensus estimates. A key insight is that these upward earnings revisions, reflected in the company’s current Zacks Rank of #3 (Hold), highlight growing confidence in AngloGold Ashanti’s near-term profitability without changing its overall rating. We’ll now examine how this recent wave of...

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

Wall Street remains very bullish on SpaceX stock.

A chipmaker and two power producers are raising forecasts and signing hyperscaler contracts while their stocks sit well off their peaks. That gap between fundamentals and price action may not last past September.

Rafal Brzoska built InPost into a parcel company in nine countries. But it wasn’t always a smooth ride.

Enterprise Products Partners has proven the durability of its high-yielding distribution over the years.

These chipmakers trade anywhere from 6 to 33 times their expected earnings for this fiscal year or next -- and the cheapest one is the one I'd be most careful buying.

Key TakeawaysBitcoin Rebound: MARA stock jumped 14% Friday as bitcoin surged near $81,000. Split Verdict: Six buys, two outperforms, four holds, one underperform and one sell make up the 14 analysts TIKR tracks on MARA stock, whose mean target of $18 sits 39% above Friday’s close.

Wood made a major Magnificent Seven purchase in the ARK Innovation ETF.

The once-high-flying fintech stock has cratered, and investors are wondering what they should do.

New tech, new governance policies, and new revenue sources are helping these coins get on to the path to recovery.

Blackstone (BX) is back in focus after reports that Brookfield Corporation is in advanced talks to buy PGP Glass for about $1.3b to $1.5b, a deal that could potentially give Blackstone a full exit from the investment. Recent price action shows that momentum around Blackstone has cooled. The stock is down 13.87% based on the 30-day share price return, and year to date the share price return has declined 21.31%. The 1-year total shareholder return is down 30.70%, compared with a 23.64% total...

Nike (NKE) just made a high profile boardroom move. The athletic giant expanded its board to twelve directors and added Alexandre Arnault from LVMH, even as it works through a difficult business reset. NIKE’s boardroom refresh comes at a challenging time, with the share price at US$35.51 after falling about 13.5% over the past 30 days and dropping 43.9% year to date. The 1 year total shareholder return is down 48.3% and the 5 year total shareholder return has declined 74.0%, pointing to...